VTC-880
Periodontitis
Phase 2Active
Key Facts
About Virtici
Virtici is a private, San Francisco-based biotech founded in 2019 that functions as an innovation engine and product developer in digital health and AI/machine learning. Its business model involves identifying and validating early-stage scientific concepts, strengthening intellectual property, and advancing them into clinical evaluation through partnerships or startup affiliates, as evidenced by its advancing pipeline. The company is currently pre-revenue, with its lead program, VTC-880 for periodontitis, in Phase 2 development via an NIH SBIR grant, and it maintains a focus on several therapeutic areas including inflammation, oncology, and autoimmunity.
View full company profile